Transcript 0:00 All right. Welcome back to the MiddleType podcast. We're here with Dr. Steven and Aaron Carithers, uh, who are building the company PrognostX Health. 0:08 Uh, so Steven and Aaron, thank you guys so much for taking the time to join us. 0:12 Uh, just as a way to, to kind of jump off here, would you guys mind just briefly going over your all's backgrounds, and we'll dive into how you got into this position to start PrognostX Health and the problem you're solving and, uh, all that sort of stuff. 0:24 Well, thanks for the introduction, and, um, thanks for having us both. So we appreciate the opportunity. Absolutely. 0:30 Uh, PrognostX Health was actually founded and established as, as a company we would like to call AM- AMDX PrognostX, uh, approximately 2020. 0:40 But we weren't really functional and operational until 2021 till we had the licensing in place and the activities and validation studies going. 0:50 But briefly, the company focuses on developing clinical diagnostics for chronic diseases. We have been focusing on chronic kidney disease, and the reason for that is the untapped... 1:02 not just the untapped market, but the unmet clinical need for chronic kidney disease and diagnosis thereof. 1:08 Um, as we develop our technologies, uh, we did find that there's, there's truly not a single assessment one-time, um, diagnostic for chronic kidney disease. 1:21 I've been diving into this field for about 20 years and working out the mechanisms that, that require certain biomarkers to be elaborated so we can actually diagnose chronic kidney disease earlier than the standard of care. 1:34 So we started that, a- and the reason we do it this way is because we like to work backwards, and we like to work forwards. 1:41 Which I mean by that is that we like to work from the bench side, from the experimentation side to the clinical side. 1:47 And then having Aaron, who's gonna describe himself in a few minutes, we're able to work backwards and forwards to meet in the middle from a clinical standpoint and from an experimental scientific standpoint. 2:00 And we do this for chronic kidney disease, but we have other chronic diseases that we're working on in the background. So we have a lead product that is 2:10 virtually ready for clinical trials, and we have done certain experiments through R&D. We've developed manufacturing. Um, but my background itself is in biochemistry and molecular biology. I am truly an academician. 2:26 You know, I'm... I, I was in academics for years before I left the university to start my own company. 25 years later, I'm still going strong. 2:35 So I've developed a certain business acumen to tackle the science of business and the business of science. [laughs] And in doing that, you become not only CEO, you become CTO, CSO, CFO, and you also take out the garbage. 2:52 So- [laughs]... you try to stay sustainable, but you also try to tackle the hard parts, and that is the experiments at hand. So we can do appropriate validation studies, so we can get to a point where we have, um, 3:06 products on the market that are truly addressing an unmet clinical need. Um, other parts of my background is I have a, a deep understanding and experience in infectious disease, renal physiology, nephrology, 3:21 uh, oncology, and I've also developed some technologies that have been licensed and have produced revenues, um, royalties in cancer diagnostics as a cancer test, also for, um, for irritable bowel disease therapeutics. 3:39 So we have experience in developing therapeutics and diagnostics, but our goal for PrognostX Health is to actually tackle one di- one disease at a time and, and truly trying to stay ahead where we can, we can confirm the future of your health now with early diagnostics for diseases that just don't have an appropriate diagnostic test. 4:01 So from that point, I will let Aaron tell you about his history. Uh- Perfect. 4:07 So, um, I graduated, uh, from the University of Kentucky with, uh, my MD in 2018, and after that started a fellowship in translational medicine, which basically takes, uh, different types of research and figure out how to apply them to different clinical needs or unmet, uh, gaps in clinical medicine. 4:27 So you actually find like, uh, what the research is actually showing and then find where that, uh, gap is. 4:34 Um, during that translational medicine fellowship, I took a, uh, a kit for, uh, pre-diabetes and tried to figure out a way how to, uh, uh, detect high-risk patients who are going to progress quickly into, uh, into, um, high-risk diabetes and develop, uh, different, uh, comorbid conditions like heart disease, brain disease, or kidney disease, uh, rather quickly, so that way those patients could be treated before they even develop diabetes themselves. 5:03 Um, during that time, we were also working on a chronic kidney disease test, uh, which was actually the correlation was discovered somewhat by accident while we were researching, uh, salt sensitivity hypertension. 5:15 Um, the correlation was discovered, but the, uh, translational medicine fellowship allowed me to take that and apply it to what is the biggest gap in clinical medicine right now and which could be applied, and that was the way that chronic kidney disease is diagnosed. 5:30 Because the real problem in clinical medicine from that standpoint is end-stage renal disease. 5:36 Um, only about a million or so people have end-stage renal disease in the United States, but it costs healthcare upwards of about $75 billion. 5:44 And, uh, uh, diagnosing chronic kidney disease was an issue, but it wasn't a huge, um... 5:52 it wasn't, uh, at, at the forefront of most physicians' minds because the only standard of care was only about 26% sensitive, and it took about three to five months of repeat testing in order for, uh, an actual diagnosis to be made Uh, over that time about 60 to 70% of the patients are lost, and so you actually have a huge gap in the amount of patients that can be diagnosed with chronic kidney disease. 6:16 Up until April 2021, um, there wasn't a big need in order to diagnose those people, so we had a tough time convincing people that a single assessment diagnostic for chronic kidney disease was, uh, very effective. 6:30 Um, but in 2021, uh, the very first therapeutic, Voxzigo, was approved to treat chronic kidney disease, which actually reduced the risk of progression to end stage by about 40%. 6:41 Uh, so all of a sudden if you can diagnose all those people with chronic kidney disease, which there's about 30 million undiagnosed people in the United States right now, and treat them, you can reduce about 40% of them from progressing to end stage, saving healthcare upwards of $20 to $30 billion a year, which is what end-stage renal disease costs. 7:01 And so, uh, since then we've taken, uh, the pre-diabetes test and we've taken the chronic kidney dis- disease test and brought them in-house underneath and called the new company Prognostic Self, where we focus on, uh, developing prognostic tests or, uh, early diagnostic tests for chronic diseases so that way they can be treated earlier, so that way, uh, they, uh, don't progress to the end stage, uh, like end-stage renal disease or high-risk diabetes. 7:28 Got it. 7:28 So to summarize, uh, the healthcare system and doctors have had a hard time preventing these chronic diseases in the early stages of, uh, pre-diabetes and, and diabetes 'cause they haven't had a test to understand what to solve as f- Mm-hmm... 7:43 as far as the problem goes. And so they're really kind of shooting in the dark unless they have a test to say, "Okay, this patient is likely to develop, uh," in your all's case, "kidney disease. 7:54 We're able to identify that earlier. Now let's start doing some preventative treatment." They haven't had that to date. Is that, that's kind of the way to summarize what you guys are doing here? Yeah, absolutely. 8:04 And, um, yeah, the, the preventative treatment really wasn't even available until April 2021, and now there's a new one that's gonna be available that just went to the FDA here in January 2023. 8:14 And so it was really difficult to convince people that the test was even worthwhile because- Yeah... you diagnose the person, what are you gonna do about it, was the- Yeah, very interesting... difficult time. Yeah. 8:24 Very str- in- interesting timing here. You know, it's, it's- Oh, right. [laughs] It's great that, you know, you guys have developed the test and now the, you know, the preventative measures are starting to follow. 8:35 Um, why, why kidney disease first? 'Cause there's other, you know, chronic diseases. Was there something you all identified about kidney disease that made you choose that one first? I'll go back to my background again. 8:47 It, it did start in colon cancer and, um, gastrointestinal diseases, but my background in infectious disease and nephrology took me to the kidney in this certain mechanism and pathway, 9:01 um, that led me to, to kidney research. So when I got into the kidney, I found that some of the, uh, very similar mechanisms exist within the kidney as they do in the intestine. 9:14 The difference is it works a little, a little opposite, where i- in, in the intestine, you try to get rid of extra metabolites and you try to get rid of, uh, extra materials, or you absorb sodium a- and other elements that you need for your body to, to actually keep a constant blood pressure. 9:33 But in the kidney it works a little differently. 9:36 A- and then what we found through this, this program is that we truly had a test that diagnosed early chronic kidney disease before the disease became evident in a doctor's office or to the patient. 9:51 Like right now you may feel okay, and you do one of our tests and you will test positive for kidney disease, that you will either have early stages of kidney disease. 10:01 And, and the reason is, is because it's such a subtle underlying mechanism, and by the time current standard of care finds that you have kidney disease, you've already lost 50% of your kidney function. 10:17 So having that experience in, in renal physiology and nephrology, uh, led us to a point where we developed a hypothesis and we started testing it between 2012 and, and probably a l- a little earlier than that, 2010 to 2020. 10:34 But we took those hypothesis and generated a more functional, commercializable test that could be used on the market. 10:41 And it took quite a few years to understand that mechanism, and then it took quite a few years to understand what components we need to make a test, and then how the test will be used in the clinic. 10:51 And if you have all these pieces of the pie in, in, in order, then you're ready for something that just exploded on us, like w- we were, we were very much looking forward to a new drug for chronic kidney disease. 11:04 It just happened, and we were staying on the forefront, and 2021 happened, the approval of the first new drug. And, and when Aaron mentioned a new drug being approved in 2023, it's not the only one. 11:15 There's a pipeline of drugs by different pharmaceutical companies. As usual, they all have their own drug, and, and we're hitting at the right time. So that's- And so they need to know who to target with that drug. 11:27 Well- So they might have the drug, but the problem is they have the drug but they haven't been able to know who to target, and now you're kind of backfilling that. That's exactly right. Mm-hmm. 11:35 I'm glad you see it that way- Yeah... because that's how we see it. Yeah, that's awesome. Yeah. That's amazing. Talk- That's cool... 11:39 talk, uh, talk real briefly about the process of commercializing, uh, you know, a test like this or technology like this 'cause you just mentioned, you know, having the hypothesis all the way back, you know, I think you said 2012 there, and then getting it all the way to this point. 11:52 I mean, this is a much different process than some of the other, you know, technology companies that we talk with that build an MVP in a couple months and get it out to market and fundraise and everything. Yeah. 12:01 So just give our listeners a sense of what all goes into creating something that, uh, is, is along the lines of this test that you guys have created. 12:10 Well, I'll start with a little bit of our pain points and choke points and, and then you really have to hear it from the clinician. So Aaron's gonna- Mm-hmm... Aaron's gonna fill in the void here. 12:18 But to develop a, a, an appropriate Clinical diagnostic that's gonna be used on the market. 12:24 Of, of course these studies all start on the lab bench, and I think everybody at the lab bench thinks they have a, a, a great test that's gonna be marketed next year a- and, and it just doesn't happen that way. 12:37 So as you develop your first studies, your feasibility studies, you have to make sure it's gonna work, and then you develop these proof of concept studies. 12:45 It takes a long time to acquire the right clinical samples, the patients, uh, they need to qualify for how your test is gonna be used. The, the second point on that, and that, that takes a little bit of time. 12:57 That takes, that takes a while, and then you have to analyze the data, but the next step after doing that is you have to validate your results in a different pool of samples, in, in a pool of samples that you've collected that are unbiased, they're collected, a- and, and you kind of - you don't try to fit it in a box. 13:16 You let the data tell you where you're gonna go. Mm-hmm. Our advantage was, is that we knew that this was, uh, involved in chronic kidney disease and the development. 13:27 Uh, the other advantage is we knew that there were no comorbidities that were interfering with the assay. So s- for example, it's not going to be interfered with those who have cardiovascular disease. 13:40 It's not gonna be interfered for those who have cancer or z- for those who are on multiple medications. 13:46 And, and so as you develop this test, you, you, you wonder, it's like is there anything that's going to interfere with how this test is gonna work on the market? So you address each one of those in pieces. 13:57 But now that you've got all the studies done, it's time to work on the regulatory part. 14:02 So this MVP model doesn't work so well for a clinical diagnostic 'cause as soon as you get it out, if I were to just put it out on the internet to sell it, uh, first of all, you're kind of liable for the, for the results. 14:15 Um, I would be tell- I would wanna tell people that you have kidney disease or not. You just can't do it that way. And then the next is Medicaid and Medicare Services, CMS is what we call it. 14:27 Um, if you start marketing your test early, before it's even established in the regulatory process, you're kind of stuck with that price point. 14:37 So if I were to just put it as an MVP for 20 bucks for people to order it, and we'll test them in the lab and send them some results, we could be stuck with that cost, and that's not truly what the cost would be for us. 14:49 It's gonna be something at the hundreds or, or, you know, between 50 and 75 bucks to run a test, and we would be trapped in a situation when if we went back to the regulatory agencies and said, "Oh, well we used to sell it for 20, but now we want $65." 15:06 It's not gonna get... It, it's just not gonna go through, and at that we need to prove some validation behind it on why we want more. Uh, other tests cost hundreds of dollars. 15:16 We would really be underselling, you know, whatever competition comes next because we've also done manufacturing, and that's another piece of the pie. cGMP manufacturing is expensive, especially for a small lab like us. 15:29 So what I mean by cGMP is that I can manufacture reagents that go into the test, research use only, so I could only sell it to laboratories. 15:39 But if I wanted the clinical diagnostic, you need to create qualified materials that are, uh, that obey the documentations and the policies instilled by the FDA. 15:51 So we do what they call current good manufacturing practices and, and we obey these policies upfront, and we've been able to do that early since we got a lot of funding upfront for the studies. 16:02 And once we qualified our cGMP materials, then we can put those materials together and actually have a kit assembled and use them for clinical trials. 16:12 So then you do clinical trials, then you go to the FDA and, and you can go on the market with cGMP qualified kit assembled test. If you go any earlier, then you've made a mistake. So Aaron, go ahead. Yeah. 16:29 Um, yeah, and then, yeah, he was talking about the clinical studies and that's, uh, you know, the early validation studies and then the, the late FDA clinical trials, and that's really where my perspective comes in because when I originally came on to the test itself, it was being investigated for heart failure and hypertension. 16:47 And they noticed that around the, the line, the cutoff line of, uh, eGFR, which is the, the current way to diagnose chronic kidney disease, that there seemed to be a little bit of a correlation, and that it would be a little bit higher, uh, on this side of the line, a little bit lower on this side of the line. 17:03 And so the, the s- strategy when I came on seemed to be that they were, um, uh, the company was trying to discern, uh, you know, who is, is above the line and who is below the line right there at the, at the cutoff. 17:17 And, um, you know, that's, that's where I kind of took a, a little bit of pi- of a, of a pivot point because, um, from my perspective, where's the biggest, um, gap in, in, in chronic kidney disease or healthcare right now? 17:30 And that's end stage, and that's the, uh, that's the amount of people who are diagnosed with chronic kidney disease, and that's about 30 million undiagnosed people. So why are there so many undiagnosed? 17:41 Because in between test one and test two, in test two and test three, per the current standard of care, 60% of people are lost each time, and then they don't come back. Mm. 17:50 And they don't have symptoms, and so they don't, uh, they don't really care to come back because most patients, about 60% of patients without any symptoms at all, aren't really going to be, you know, really triggered to come back. 18:01 The thing is, is that it's progressing and that it's continuing to get worse, and now that there's treatment available, uh, there's, uh, there's a huge need to get all of those people diagnosed. 18:12 So what would be the biggest, um, what would be the biggest unmet clinical need? And that's a single assessment diagnostic for chronic kidney disease. Eliminate that follow-up. 18:21 And so we redesigned the whole clinical study And measured out a way to where we could discern whether or not we were diagnosing people at, at one time, uh, who had CKD or versus one time who did not have CKD. 18:34 And we were about 98% sensitive and about 97, uh, percent specific. Mm-hmm. And so there we have our, our market gap, and that goes into designing the rest of our clinical studies too. Yeah. 18:45 The current standard of care is only 26% accurate. We are 97% accurate, so even if it falls a couple percent, 18:55 the amount of people that we could actually address and save healthcare is about $300 million just in the US alone. So I think we have a pretty significant 19:07 advantage, not only in our test, but we're addressing a really important part that is, that is causing a healthcare bubble. Yeah. Yeah. It sounds like it. That's, that's, that's amazing. How... 19:17 You mentioned there this is a long process. There's a lot that goes into this testing and developing the product. How have you guys approached funding? 19:24 You mentioned you, you've taken a lot of it, you've taken a lot of funding. How has the state helped with that and, and where are some other sources that maybe that funding's coming from? 19:32 Well, the state has provided what we call that additional depth. We would get grants from federally funded institutions, but the state matches those grants with, with ways that we can go deeper in our studies. 19:48 We can add more clinical samples and, and patients to our study base. We don't use it to develop manufacturing because the grants, the initial grants have, have, have taken care of that. 19:59 But what we do is we learn a little bit more about the commercialization process. 20:04 As Aaron said, part of his training with the, uh, the translational medicine a- and his postdoctoral fellowship, part of that was kind of funded through the state, but it allowed him to do some programs and meet the right people. 20:17 Because not only does the state funding allow us to do some experiments a- and go deeper in our studies, but allows us to go shop for people who can help us commercialize our diagnostics, and that's exactly what we did. 20:31 We went and got some, what I like to call pros in the field, who have actually launched their clinical diagnostics from almost lab bench level, but from an early stage to a late stage. 20:43 You know, our current, uh, chief business development officer sold her latest diagnostic kit to LabCorp for 155 million. Well, they're somebody we want on our team because she's done it. 20:56 She's worked with the right people. 20:58 Uh, also, she's, she's been able to work with Pfizer, AstraZeneca, Johnson & Johnson, so she works with companies that we are definitely interested in working with 'cause they have the therapeutics. 21:10 She understands the, um, should I say the, the pathway to success when you get to a point like we're at. And, and so that's... I- I hope that makes sense, but the state funding has been phenomenal for us. 21:26 It, it kept us afloat. Uh, uh, I think it's important to say that because without them, I don't think we'd be here. 21:33 Uh, I think we'd both have different jobs or running different companies or, or doing something, but the state has allowed us to further develop this. 21:40 And if we bring these studies here in the state, it, it's just amazing that we could probably even bring the manufacturing in state and create jobs. Now- Hmm... 21:51 we won't do the manufacturing, but I will be able to farm out the manufacturing to appropriate facilities here in the state that are now in place, and it's a lot of jobs, it's a lot of people, it's a lot of tax revenue back to the state. 22:04 Um, I'd like to say we can return the favor. That's awesome. That's a great goal to have. 22:09 And we talked, y- you know, you talked a lot about how big of a problem this is and how much of an improvement, um, your all's test is, is gonna be in this market. 22:17 Uh, let's switch over to a little bit of like the business conversation around this and, and the market you all are going after. One, ki- how, how is a company like you all's valued? 22:26 Like, what's, what's the value you guys are chasing after in terms of how big you want, you wanna see this company get and, and how is it... 22:32 You know, how do other companies in the market, you know, look at you guys, uh, and how big is the market that you're, you're going after? 22:40 Well, you wanna start with the market numbers, and I'm gonna tell you where we fit in to the pie. [laughs] Yeah. 22:46 And yeah, that goes along kind of with the trials as well 'cause we, uh, we've, we've redesigned kind of the whole concept now and the whole, um, the IP portfolio and a new patent's coming out later this year that's specifically directed in testing high-risk patients. 23:01 So patients who are at high risk of developing chronic kidney disease would come in for screening with this test and, uh, and, and get a diagnosis before they start, um, exhibiting symptoms. 23:12 And those, uh, main populations are those with diabetes, uh, those with hypertension, and those who have recently experienced some kind of acute kidney injury or, uh, nephropathy or have some kind of, um, you know, albumin in their urine. 23:27 Uh, but specifically, you know, the, the mega populations that we need to be testing are those with hypertension and diabetes. 23:32 They contribute to almost 80% of all CKD cases, which then correlate, which then translate into the end stage renal disease cases too. 23:40 So if we can make that diagnosis, um, you know, earlier then with diabetes and hypertenses, then we can, uh, you know, start the treatment and stop the progression. 23:49 About 116 million people have hypertension, and about 37 million people have diabetes in the United States alone. 23:57 And, you know, plus or minus, uh, you know, diabetics, two in three diabetics probably have hypertension, so you're looking at a population of about 130 million people who probably need to be screened in the United States every year. 24:09 Hmm. Um, because there's about 40 million with chronic kidney disease and, you know, maybe 70% of those, uh, are undiagnosed right now, which means they're untreated and progressing. 24:18 And so we're chasing a huge market, um, and we really are taking a lot of careful steps to make sure all the intellectual property is locked down and that it protects not only the platform that it's on, but also like the clinical method in which we, uh, expect it to be used in the clinic and to make a, a- Plus, minus, um, threshold, you know, cutoff diagnosis. 24:40 Treat, no treat, plus, minus, um, as, as simple as possible so that way the physician can understand, you know, what the test result actually means as far as physiologically and why this treatment is likely to, uh, slow the progression of the disease, and why it's important. 24:57 Um, and so with the, the second patent coming out this year, it's time to probably get the, uh, the PR going and the marketing going a little bit because, uh, the publications are essentially kind of the marketing. 25:10 And so we expect the publications to start here later this month, and then we're gonna follow up with peer-reviewed, and then, uh, that acts as like our little launchpad into the, into the public eye, uh, in a way. 25:22 And that goes along with how we're raising money now, which is a Series A fundraising round, um, to, uh, to generate enough, uh, enough capital to get through the FDA clinical studies, the manufacturing, uh, and to launch a, a laboratory developed test, uh, with the product too, which is small scale and isn't necessarily covered by insurance right away. 25:44 But it starts to gather data, and then that data can then be used to go to the FDA, can be used to go to the CMS. 25:51 And so it's a bit lengthier of a process if we had like, you know, a billion dollars, you know, going a little step at a time. But it protects, uh, the product better. 26:00 It, it slowly inches it out on the market so we don't overstep too quickly and then, you know, lose, uh, everything or get scooped. [laughs] Mm-hmm. Yeah. 26:08 So Logan, about the business side, I, I think you brought up a good question because what is our value? And our value does rest in our intellectual property. Sure. I think that's part of it. 26:19 Our other value does rest in the marketplace where the niche that we fit into. Uh, the last value we have, which I think is, is one of the best, is that we are able to look at early stage and promising technologies. 26:33 So the idea of that is that we want to produce a kit that's ready to be marketed, but we are not that big marketing company. 26:43 Someone that is much larger, a clinical diagnostic company or a pharmaceutical company with a global reach, that's who we want to provide this test to so they can do all the marketing, they can do all the commercials, they can do whatever they do to get the product into the clinic. 27:00 That is not us, and I think we've come to that realization that we don't want to grow that type of company. 27:06 But what we'll do is go right back and develop the next diagnostic test that needs to be developed and serve it on a silver platter to the next company. That's the, the middle ground that us small biotechs can serve. 27:20 Um, and I'd even... You've-- everyone has heard of the word Bi- BioNTech, who works with Pfizer, but they were small. A long time ago, they were small working on their, their products, and now look at them. 27:32 They're, they partnered with Pfizer, but they are this small biotech who developed something that was just a unique technology, and it worked out great a- and look how it, you know, saved so many people. 27:44 Um, I'm not saying we're BioNTech. We, we are not. 27:48 But we are certainly good at what we do, and we don't mind staying small and, and being those people who can produce the next clinical diagnostic or even therapeutic if it falls into our laps. I hope that makes sense. 28:02 I love it. It does, absolutely. And you guys laid out a bunch of great kind of where you're looking into the future, which was, was kind of the next question that we had. 28:11 Um, but you guys painted a great picture of going after, you know, some Series A funding to get there, how you're gonna navigate the FDA, um, trials and all, all of that sort of stuff, collecting data around, around the tests that you're administering. 28:21 So, uh, you know, we just want to say thanks again for, for taking the time to come on here. 28:26 Uh, this is definitely one of the more in-depth, uh, companies that we've talked to in terms of the knowledge needed to develop technology like this. 28:33 So congrats to you guys for getting to the point that you've gotten to, and, uh, we're excited to watch your all's continued growth. Oh, we sure appreciate the opportunity. Yeah, we- yeah, really appreciate it. 28:42 This was fun. [outro music]